We are studying a new treatment for people aged 12 to 65 with allergic rhinitis caused by house dust mites. The trial will evaluate its effectiveness and safety compared to a placebo.
We are evaluating a new DNA vaccine to see if it is safe and can help the body fight against Crimean Congo Hemorrhagic Fever. This study is for healthy volunteers who want to contribute to vaccine research.
We are studying whether ianalumab can improve kidney function in people with active lupus nephritis compared to a placebo. This trial also looks at the safety and tolerability of the treatment.
We are testing a personalized gene therapy for patients with advanced head and neck cancer. The goal is to see if it can improve treatment outcomes compared to standard options.
We are comparing personalized radionuclide therapy with standard treatment for patients with neuroendocrine tumors. The goal is to see which approach is safer and more effective in shrinking tumors and improving quality of life.
We are exploring how well two medications work for kidney health in people with type 2 diabetes. This remote trial aims to personalize treatment based on individual responses.
We are exploring whether a treatment-free interval is safe and effective for newly diagnosed multiple myeloma patients receiving a combination of Daratumumab, Lenalidomide, and Dexamethasone. The study aims to compare the effects of continuous treatment versus a break in therapy.
We are studying a new treatment combining naxitamab and GM-CSF for children with high-risk neuroblastoma who have not responded to prior therapies. The trial aims to assess how well this treatment works and its safety.
We are investigating whether AZD0305, alone or with other cancer therapies, is safe and effective for adults with relapsed or refractory multiple myeloma.
We are studying whether FDG-PET/CT can better monitor treatment response in metastatic breast cancer patients compared to conventional CT. This may help improve survival and quality of life for those involved.
We are studying whether adding Gembrax to the standard Folfirinox treatment helps patients with metastatic pancreatic cancer. This trial aims to find out if the combination is more effective than Folfirinox alone.
We are studying two new medications to see if they can help prevent blood clots in adults with a peripherally inserted central catheter. The trial will also assess how safe these treatments are.
We are investigating whether empagliflozin can help increase sodium levels in patients with euvolemic or hypervolemic hyponatremia. The study will also look at its effects on related symptoms and overall health.
We are comparing a new treatment combination for advanced melanoma that has worsened after other therapies. The goal is to see if this combination improves survival and response compared to standard treatment options.
We are studying whether dostarlimab can improve outcomes for adults with locally advanced head and neck cancer after initial treatment. Participants will receive either the new treatment or a placebo to compare effects.
We are studying whether adding extracorporeal photopheresis to corticosteroids helps patients with Grade II acute graft-versus-host disease after stem cell transplantation. This trial compares treatment outcomes and side effects between the two approaches.
We are studying a combination of ENCORAFENIB and FOLFIRI for patients with BRAF V600E mutated metastatic colorectal cancer that has progressed on previous treatments. The goal is to see if this combination can improve treatment outcomes and safety.
We are studying whether doravirine is as effective as dolutegravir for people newly diagnosed with HIV-1. The trial also examines potential side effects and health changes over time.
We are studying two treatment reduction strategies for patients co-infected with HIV-1 and HBV to see how safely they can manage their viral infections. The trial will also look at the impact on quality of life and any potential side effects.